High expressions of galectin-1 and VEGF are associated with poor prognosis in gastric cancer patients

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2513-2519

  Chen, Jie ^b,c   Tang, Dong ^a   Wang, Sen ^d   Li, Qing Guo ^a   Zhang, Ji Ran ^a   Li, Ping ^a   Lu, Qi ^a   Niu, Gang ^a   Gao, Jun ^a   Ye, Nian Yuan ^a   Wang, Dao Rong ^a  

^a YANGZHOU UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Galectin 1; Gastric cancer; Prognosis; Survival; VEGF

Indexed keywords

GALECTIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR VOLUME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GALECTIN 1; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899074940     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1332-8     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
3. Sakaguchi M, Imaizumi Y, Okano H. Expression and function of galectin-1 in adult neural stem cells. Cell Mol Life Sci. 2007;64:1254-8.
4. Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta. 1999;1473:172-85.
5. Banh A, Zhang J, Cao H, et al. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 2011;71:4423-31.
6. Kovacs-Solyom F, Blasko A, Fajka-Boja R, et al. Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett. 2010;127:108-18.
7. Thijssen VL, Barkan B, Shoji H, et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010;70:6216-24.
8. Han H, Silverman JF, Santucci TS, Macherey RS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8:72-9.
9. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-705.
10. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-27.
11. Mizokami K, Kakeji Y, Oda S, et al. Clinicopathological significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncol. 2006;94:149-54.
12. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible factor 1 alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst. 2004;96:946-56.
13. Saito H, Tsujitani S, Ikeguchi M, et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer. 1998;78:1573-7.
14. Saito H, Tsujitani S, Oka S, et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999;86:1455-62.
15. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341-53.
16. Watanabe M, Takemasa I, Kaneko N, et al. Clinical significance of circulating galectins as colorectal cancer markers. Oncol Rep. 2011;25:1217-26.
17. Jung EJ, Moon HG, Cho BI, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer. 2007;120:2331-8.
18. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology. 2006;16:137R-57R.
19. Chiariotti L, Salvatore P, Frunzio R, Bruni CB. Galectin genes: regulation of expression. Glycoconj J. 2004;19:441-9.
20. Zhao XY, Chen TT, Xia L, et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis. 2010;31:1367-75.
21. Wu MH, Hong TM, Cheng HW, et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res. 2009;7:311-8.
22. Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006;103:15975-80.
23. Barrow H, Rhodes JM, Yu LG. The role of galectins in colorectal cancer progression. Int J Cancer. 2011;129:1-8.
24. Dalotto-Moreno T, Croci DO, Cerliani JP, et al. Targeting galectin-1 overcomes breast cancer associated immunosuppression and prevents metastatic disease. Cancer Res. 2013;73:1107-17.
25. Laderach DJ, Gentilini L, Giribaldi L, et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013;73:86-96.
26. Demydenko D, Berest I. Expression of galectin-1 in malignant tumors. Exp Oncol. 2009;31:74-9.
27. Puchades M, Nilsson CL, Emmett MR, et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res. 2007;6:869-75.
28. Kleespies A, Bruns CJ, Jauch KW. Clinical significance of VEGFA,-C and -D expression in esophageal malignancies. Onkologie. 2005;28:281-8.
29. Donnem T, Al-Shibli K, Andersen S, Al-Saad S, et al. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer. 2010;116:4318-25.
30. Linderholm BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer. 2003;4:340-7.
31. Kosem M, Tuncer I, Kotan C, et al. Significance of VEGF and microvascular density in gastric carcinoma. Hepatogastroenterology. 2009;56:1236-40.
32. Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther. 2005;4:315-21.
33. Koopmans SM, Bot FJ, Schouten HC, Janssen J, et al. The involvement of galectins in the modulation of the JAK/STAT pathway in myeloproliferative neoplasia. Am J Blood Res. 2012;2:119-27.
34. Fischer I, Schulze S, Kuhn C, Friese K, et al. Inhibition of RET and JAK2 signals and upregulation of VEGFR3 phosphorylation in vitro by galectin-1 in trophoblast tumor cells BeWo. Placenta. 2009;30:1078-82.
35. Hsieh SH, Ying NW, Wu MH, Chiang WF, et al. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 2008;27:3746-53.
36. Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer. 2003;97:1849-58.